Technologies

The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs,  requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.

SITODIET is an innovative software that supports a translational approach to health’s state. It integrates various sources of physiological, behavioral, and psychological data to reduce the risks associated with the onset of lifestyle-related diseases (primary prevention), to support health professionals in early diagnosis (secondary prevention) or to manage the personalized therapy’s patient (tertiary prevention). SITODIETcollects data automatically, through actigraphy tools, as wristband or smartwatch, or manually